<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58536">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343978</url>
  </required_header>
  <id_info>
    <org_study_id>KWA1205</org_study_id>
    <nct_id>NCT02343978</nct_id>
  </id_info>
  <brief_title>Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of KWA-0711 in Chronic
      Constipation (CC) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Chronic Constipation（CC）</condition>
  <arm_group>
    <arm_group_label>KWA-0711 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KWA-0711 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KWA-0711</intervention_name>
    <arm_group_label>KWA-0711 High dose</arm_group_label>
    <arm_group_label>KWA-0711 Low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients who experienced fewer than three Spontaneous Bowel Movements (SBMs) per
             week for more than 6 months prior to the enrollment

          -  The patients who experienced one or more of the following signs or symptoms during
             more than 25% of bowel movements for more than 6 months: straining, lumpy or hard
             stools, and a sensation of incomplete evacuation

        Exclusion Criteria:

          -  Patients who have secondary constipation caused by systemic disorder

          -  Patients who have organic constipation

          -  Patients who received intestinal resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 15, 2016</lastchanged_date>
  <firstreceived_date>January 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Constipation</keyword>
  <keyword>CC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
